• Lead the finance and accounting function, including financial forecasting, budgeting, and general Financial Planning and Analysis. • Lead the business development function, including the technical and commercial evaluation of potential business development opportunities, negotiating and structuring agreements, and the execution and integration of transactions in support of the corporate strategy• Lead commercial assessment and indication prioritization for internal programs• Lead market research and competitive analysis activities• Lead the procurement function, including IT procurement and management of external IT service providers

Focused on developing the Servier Pharmaceuticals portfolio by actively looking for acquisition of licenses, products, or any other form of partnership, in strategic therapeutic areas.Led the due diligence, valuation, and integration of the $1.8B acquisition of the Agios Oncology business.· Primary contact for partnership opportunities with the US Servier business · Piloting scientific, medical and economic evaluations of the projects, in close collaboration with internal and external experts;· Supporting strategy development initiatives to identify strategic business priorities;· Coordinating evaluation of opportunistic business leads

• Coordinated 2018 quarterly and annual ‘Profit forecast’ report for Board of Directors, 2019 Budget process, and development of three year ‘Mid-Range Plan’ • Lead for the Purchase Price Allocation process for Shire assets in Takeda acquisition

Key responsibilities of the role: Leading cross functional valuation assumptions, and due diligence meetings; Ownership of the financial modeling; Partnering in the creation and negotiation of deal terms; Reviewing legal documents and setting the financial terms • Corporate level initiatives: core team member for the Neuroscience Strategic review, and the Takeda takeover negotiations and due diligence with specific focus on business valuation, corporate/franchise strategy, capital structuring, and various other tactical, business, and operational matters. • Mergers, acquisitions, and in-licensing: completed numerous business valuations for possible acquisition targets, completed licensing agreements with Parion Sciences, Novoimmune, and various other commercial collaboration agreements. • Divestments: Oncology, and the Rare Gastrointestinal businesses: completed the financial deal model, presented the business to bidders, lead the financial due diligence process, reviewed and edited the definitive agreement • Early stage research agreements: Review of the all financially related contractual terms for multiple agreements

• Secretary of the Inline Committee, the company governance body responsible for commercial execution, strategic portfolio reviews, endorsement and input for late phase development programs. • Managed the International Leadership Team and acted as the International Commercial representative of Corporate Committee • Central coordinator for the NPS Pharmaceuticals integration for all international countries • Provided oversight to the Rare Disease Excellence and Launch Excellence programs • Led all Investor Relations and senior management presentations for International Commercial

• Provided strategic financial partnership and leadership to the regions commercial teams to achieve financial results through close collaboration and providing key insights and recommendations. • Provided financial leadership for Shire’s commercial expansion business cases including acquisition of Solpharm to gain better access to Central and Eastern European markets.

• Finance lead for HAE Franchise as part of the Global Development and Product Strategy teams • Managed franchise strategic Long Range Planning process, and contributed to numerous business cases

• Oversaw the financial operations, advised on investment plans, monitored the financial performance, and produced financial reports. • Worked closely with management to develop and implement strategies and plans to achieve the company’s long-term objectives.

Financial Planning and Analyst Europe• Provide Ad hoc Analysis on Financial Results and Trends• Monthly P/L Forecasting• Capital Expenditure Forecasting• Balance Sheet Forecasts and Analysis• Initiative and Project Profitability Analysis• Proactively contribute to Continuous Process Improvements in Financial planning and analysis• Analysis of Exceptions in Operating Results• Input to Action Plans to Improve Results.• Contribute to BOS Metric Development, Communication and associated Action Plans.• Strategic Planning Input• Preparation of Annual Business and Capital Plans• Support for Senior Management Presentation

• Planned, led, and executed a project that incorporated Lean and Six Sigma tools for green belt certification. • The project outcome enabled the identification of proper payment for millions of shipped items annually by the creation of a database that tracks customer information to individual label serial numbers.

• Responsible for the design, measurement, forecasting, and objective setting of various Key Performance Indicators within the customer service team. • Developed automated reporting tools that regularly publish key performance metrics at thousands of CPC business locations. • Responsible for SAP Business Warehouse updates of the CPC executive balanced scorecard. • Developed data based ‘workload’ models that described the functional time requirements for CPC plant employees, and allowed scenario testing to determine the impact of new project initiatives. • Developed calibration models for a risk based verification system that improved efficiency of CPC verification processes of 1.5 million transactions per year of a value greater than $2.2 billion dollars in revenue at the 23 largest CPC plants.

• Identified and met with prospects to assess financial goals• Created individual financial plans• Coached clients on what products and methods could help reach their identified goals.